PET Using a GRPR Antagonist (68)Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients

This study was designed to analyze the safety, biodistribution, and radiation dosimetry of a gastrin-releasing peptide receptor (GRPR) antagonist PET tracer, (68)Ga-RM26; to assess its clinical diagnostic value in prostate cancer patients; and to perform a direct comparison between GRPR antagonist (...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Nucl Med
Glavni autori: Zhang, Jingjing, Niu, Gang, Fan, Xinrong, Lang, Lixin, Hou, Guozhu, Chen, Libo, Wu, Huanwen, Zhu, Zhaohui, Li, Fang, Chen, Xiaoyuan
Format: Artigo
Jezik:Inglês
Izdano: Society of Nuclear Medicine 2018
Teme:
Theranostics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6004560/
https://ncbi.nlm.nih.gov/pubmed/29123014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.117.198929
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items